Navigation Links
Dr. Thomas Werner Elected to Accera, Inc.'s Board of Directors
Date:3/24/2009

BROOMFIELD, Colo., March 24 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, announced today that Thomas Werner, Ph.D. has been elected to its board of directors.

Since 2001, Dr. Werner has been a managing director and senior vice president of GlaxoSmithKline (GSK) and has served as CEO of the GSK Foundation until earlier this year. He led the Pharmaceutical Research Manufacturers of America (PhRMA) in Germany as its chairman through November 2008. He began his pharmaceutical career with Squibb Pharma Germany where he held sales, marketing and brand management positions from 1983-1989 and later held executive management positions at Bristol-Myers Squibb. Dr. Werner earned his Ph.D. in chemistry at the University of Gottingen in Germany.

Dr. Werner was instrumental in the successful growth strategies and leadership of the German subsidiaries of GSK and Bristol-Myers Squibb. He grew sales of the ACE inhibitor, Captopril, to become the largest pharmaceutical product in Germany, and developed Viani, an asthma drug, into one of the leading pharmaceutical products in Germany.

Dr. Werner co-founded the Genetic Research Center, a joint venture with the Max Planck Institute for Psychiatry and the Ludwig-Maximilians-University, both in Munich. He is a member of the Board of Trustees of the Paul Ehrlich Association and the Robert Koch Foundation.

"We are delighted to welcome Dr. Werner to our board of directors," said Steve Orndorff, Ph.D., Accera's founder and CEO. "Thomas has a demonstrated record of success in the management and leadership of European subsidiaries of internationally acclaimed pharmaceutical companies. With Accera's recent US product launch of Axona(TM) for Alzheimer's disease, Dr. Werner's experience in the commercialization of several highly successful drug products will be invaluable."

About Accera, Inc.

Accera, Inc., a privately held biotechnology company, discovers and develops therapeutic breakthroughs in central nervous systems disorders. Accera's novel approaches positively impact patients with neurodegenerative disorders who are in need of effective, well-tolerated therapies. Through its proprietary scientific platform, Accera is developing products that address metabolic deficiencies associated with certain neurodegenerative diseases by providing an alternative energy source for the brain. For more information, visit www.accerapharma.com.

    Contacts:                              Richard Lewis Communications, Inc.
    Accera, Inc.                           (212) 827-0020
    (303) 999-3710                         Gregory Tiberend, Media
    Steve Orndorff, Ph.D.                  gtiberend@rlcinc.com
    Founder, President and CEO             Cecelia Heer, Investors
    sorndorff@accerapharm.com              cheer@rlcinc.com


'/>"/>
SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
2. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
3. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
4. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
5. eResearchTechnology, Inc. to Present at the Thomas Weisel Healthcare Conference on September 4th, 2008
6. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Conference
8. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
9. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
10. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
11. Volcano Presentation at Thomas Weisel Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... , ... July 20, 2017 , ... ... to make clinical trial sites and study participants truly unified. TrialKit, a native ... (FDA 21 CFR Part 11) research studies entirely on mobile devices. With TrialKit, ...
(Date:7/18/2017)... ... , ... G-CON today announced that it has received Notices ... Applications 14/858,857 and 13/669,785 both entitled Modular, Self-Contained, Mobile Clean Room. The U.S. ... of G-CON’s R&D investments and validate the G-CON platform as a novel way ...
(Date:7/17/2017)... ... , ... Whitehouse Laboratories is excited to announce that it ... of ISO 80369 standard test procedures. The ISO 80369 series of eight test ... With this recent expansion, Whitehouse Labs becomes one of the only facilities in ...
(Date:7/17/2017)... ... July 17, 2017 , ... Neurodevelopmental disorders (NDDs) are ... overlapping clinical features. The advancement of targeted next-generation sequencing (NGS) has been instrumental ... testing. , However, designing a custom panel for disease research requires hours ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
Breaking Biology News(10 mins):